A STUDY ON ENDOCRINE DISORDER IN PATIENTS WITH CHRONIC-RENAL-FAILURE .1. SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN GASTRIN-I

被引：0
|
作者：
ABIKO, T
ONODERA, I
SEKINO, H
机构：
来源：
CHEMICAL & PHARMACEUTICAL BULLETIN | 1982年 / 30卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：2604 / 2610
页数：7
相关论文
共 16 条
  • [11] CORRECTION OF ANEMIA OF CHRONIC-RENAL-FAILURE WITH RECOMBINANT HUMAN ERYTHROPOIETIN - SAFETY AND EFFICACY OF ONE YEARS TREATMENT IN A EUROPEAN MULTICENTER STUDY OF 150 HEMODIALYSIS-DEPENDENT PATIENTS
    SUNDAL, E
    KAESER, U
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (11) : 979 - 987
  • [12] A STUDY OF THE DELIVERY-TARGETING CONCEPT APPLIED TO ANTINEOPLASTIC DRUGS ACTIVE ON HUMAN OSTEOSARCOMA .1. SYNTHESIS AND BIOLOGICAL-ACTIVITY IN NUDE-MICE CARRYING HUMAN OSTEOSARCOMA XENOGRAFTS OF GEM-BISPHOSPHONIC METHOTREXATE ANALOGS
    STURTZ, G
    APPERE, G
    BREISTOL, K
    FODSTAD, O
    SCHWARTSMANN, G
    HENDRIKS, HR
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1992, 27 (08) : 825 - 833
  • [13] TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA OF CHRONIC-RENAL-FAILURE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - A EUROPEAN MULTICENTER STUDY IN 142 PATIENTS TO DEFINE DOSE REGIMEN AND SAFETY PROFILE
    SUNDAL, E
    BUSINGER, J
    KAPPELER, A
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1991, 6 (12) : 955 - 965
  • [14] Phase I/II study of the biological activity of all-trans retinoic acid in patients with Ph(1)(+) chronic myeloid leukemia.
    Sacchi, S
    Regazzi, MB
    Avvisati, G
    Dastoli, G
    Gallieni, P
    Grassi, C
    Lazzarino, M
    Liberati, AM
    Maiolo, AT
    Pelicci, PG
    Rupoli, S
    Visani, G
    Russo, D
    BLOOD, 1996, 88 (10) : 3532 - 3532
  • [15] AMELIORATION OF ANEMIA DID NOT CORRELATE TO BLOOD-PRESSURE AND ENDOTHELIN-1 LEVELS IN EARLY PHASE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT IN NON-DIALYZED CHRONIC-RENAL-FAILURE PATIENTS
    MATSUSHIMA, H
    KAWAMURA, T
    KAMATA, T
    MUSO, E
    SASAYAMA, S
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 564 - 564
  • [16] First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
    Marron, T.
    Rosen, S.
    Orr, D.
    Powderly, J., II
    Khaskhely, N.
    Bonham, L.
    Nelson, M.
    Taromino, C.
    Taylor, D.
    Kumer, J.
    Ellmark, P.
    Fritzell, S.
    Ambarkhane, S. V.
    Huebner, D.
    Alahmadi, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S524 - S525
12